

ADDRESSES: Licensing information and a copy of the U.S. patent application listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

High Throughput Screening for Cancer Genes

Liotta et al. (NCI)

DHHS Reference No. E-209-2003/0-US-01 filed 28 Apr 2003

Licensing Contact: Catherine Joyce; 301/435-5031; joycec@mail.nih.gov.

The invention relates to the discovery of an assay system in *Drosophila* that is useful for (i) identifying genes that are functionally required for invasion and metastasis and (ii) screening for drugs that block tumor growth and metastasis. The system employs the *lgl* mutation in flies. Isolated *lgl* neoplastic tissues from imaginal discs and brain tissue of *lgl* larvae grow and metastasize rapidly upon transplantation into wild-type flies.

In the first embodiment of the assay system, random insertions into genes in the *Drosophila* genome are made using P-elements. Flies are bred to obtain larva that are homozygous for the *lgl* deletion and homozygous for a specific P-element insertion, and larval tissue is transplanted into an adult host to identify mutations that modulate *lgl* tissue tumorigenesis and metastasis phenotype in the host. Mutated genes can be readily cloned using the P element as tags. The inventors have successfully used this system to identify a link between class 5 semaphorins and cancer.

In the second embodiment of the assay system, *lgl* neoplastic tissue is introduced into an adult fly comprising a functional *lgl* gene, and a candidate therapeutic agent is introduced into the nutrient medium on which the fly, and/or larval forms of the fly, feed. The ability of the candidate therapeutic agent to modulate the pattern of tumor growth in the fly is then assessed by qualitative and quantitative measurements of abnormal cell proliferation in the flies.

This technology is available for licensing on a non-exclusive basis.

Dated: January 12, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04-1022 Filed 1-15-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, National Cancer Institute.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Advisory Committee to the Director, National Cancer Institute.

Date: January 22, 2004.

Time: 12:30 p.m. to 2 p.m.

Agenda: The purpose of the meeting will be to discuss the Sarcoma Progress Review Group Report.

Place: National Cancer Institute, Bldg. 31, Rm. 11A03, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Cherie Nichols, Executive Secretary, National Cancer Institute, National Institutes of Health, Building 31, Room 11A03, Bethesda, MD 20892, (301) 496-5515.

This notice is being published less than 15 days prior to the meeting due to scheduling conflicts.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: deainfo.nci.nih.gov/advisory/joint/htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: January 12, 2004.

Anna P. Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-1017 Filed 1-15-04; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, DNA GENO Typing Review Meeting.

Date: February 10, 2004.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate contract proposals.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Irina Gordienko, Scientific Review Administrator, Division of Extramural Activities, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7180, MSC 7924, Bethesda, MD 20892, 301-435-0270.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 9, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-1020 Filed 1-15-04; 8:45 am]

BILLING CODE 4140-01-M